Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
Karnofsky Performance Status (KPS) is a clinician-rated functional scale from 100 (normal activity) to 0 (dead). It is used in oncology and palliative care to quantify disability, support prognostic discussions, and guide treatment intensity considerations.
Formula: Clinician-assigned ordinal score from 100 to 0 based on functional independence and care needs.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
The Karnofsky Performance Status (KPS) is a clinician-rated scale from 100 (fully normal) to 0 (dead), assigned in 10-point increments. Begin by asking the patient (and caregivers if present) about their current activity level: 'Are you still working or doing normal activities? Can you take care of yourself at home — cooking, bathing, dressing? How much time do you spend in bed? Do you need help with daily tasks?' Also observe the patient during the visit: appearance, energy level, gait, and ability to get on/off the examination table all contribute to the assessment. Review the chart for recent functional changes (new hospitalizations, weight loss, declining mobility). The assessment should take 1–2 minutes and can be integrated into the routine history and physical.
Match the patient's functional status to the KPS descriptors: KPS 100: Normal, no complaints, no evidence of disease. KPS 90: Able to carry on normal activity; minor signs or symptoms of disease. KPS 80: Normal activity with effort; some signs/symptoms. KPS 70: Cares for self; unable to carry on normal activity or do active work. KPS 60: Requires occasional assistance; cares for most personal needs. KPS 50: Requires considerable assistance and frequent medical care. KPS 40: Disabled; requires special care and assistance. KPS 30: Severely disabled; hospitalization indicated; death not imminent. KPS 20: Very sick; hospitalization necessary; active supportive treatment needed. KPS 10: Moribund; fatal processes progressing rapidly. KPS 0: Dead. Use only 10-point increments — intermediate values (e.g., 75) are not standard and reduce reliability. If uncertain between two values, assign the lower (more impaired) score.
Apply KPS within clinical context: KPS 80–100 (good PS): Patient is functional and can tolerate standard chemotherapy, clinical trial enrollment, and aggressive treatment strategies. KPS 60–70 (marginal PS): Patient is ambulatory but limited — consider dose reduction, less intensive regimens, or supportive care augmentation. ECOG 2 range. KPS 40–50 (poor PS): Patient requires significant assistance — chemotherapy is often too toxic; prioritize supportive care, symptom management, and palliative care referral. KPS 50 is the threshold used in many hospice eligibility criteria. KPS ≤30 (severely impaired): Hospitalization-level care needed; cytotoxic chemotherapy is contraindicated in most cases; hospice appropriate. KPS decline over time is an independent prognostic indicator: a drop of ≥20 points/month predicts poor survival. Track KPS at every visit and document longitudinal trends in the medical record.
Medical oncologists and hematology-oncology fellows
Assess KPS at each oncology visit to guide chemotherapy eligibility and dose intensity decisions. KPS ≥70 (ECOG 0–1) supports standard-dose combination chemotherapy, with the expectation of adequate treatment tolerance. KPS 50–60 (ECOG 2) requires individualized assessment — consider single-agent therapy, dose-reduced regimens, or close toxicity monitoring. KPS ≤40 (ECOG 3–4) represents a contraindication to cytotoxic chemotherapy in most settings, where treatment-related mortality may exceed cancer-related mortality. Use KPS as an objective anchor in shared decision-making conversations: 'Your current performance status (KPS 60) means your body has moderate limitations — we can still try treatment, but we need to start carefully and watch closely for toxicity.'
Clinical research coordinators and oncology trial investigators
KPS is a standard eligibility criterion in oncology clinical trials. Most phase II and III trials require KPS ≥70 (ECOG 0–1) for enrollment. Some trials of less toxic agents (oral targeted therapy, immunotherapy, hormonal therapy) allow KPS 60. Screen every trial candidate for KPS at baseline. Be aware that KPS scoring can have inter-observer variability — standardize assessments within the research team by reviewing anchor case examples. When KPS is borderline (e.g., patient appears KPS 60 or 70), err toward the more conservative score for trial eligibility to avoid enrolling patients unlikely to complete protocol therapy and confounding efficacy outcomes.
Palliative care physicians, hospice nurses, and oncologists
KPS ≤50 is one of the key clinical indicators supporting Medicare hospice eligibility for cancer patients when life expectancy is estimated ≤6 months. Document KPS at each visit and note the trajectory: 'KPS 70 at last visit, now KPS 50 — functional decline of 20 points over 6 weeks indicating disease progression.' CMS hospice guidelines for cancer specify that KPS ≤50 combined with disease progression, weight loss, and declining performance support hospice certification. KPS is also used in the Palliative Performance Scale (PPS), which maps directly to KPS values and is widely used by hospice nurses for prognosis documentation.
Oncologists, palliative care clinicians, and hospitalists
KPS is a powerful independent prognostic factor across most solid tumor types. Across multiple systematic reviews, KPS ≥70 is associated with significantly better overall survival than KPS <70, independent of tumor type and stage. Use KPS as a objective anchor in prognostic discussions with patients and families: 'Based on your performance status score of 40 and the pattern of disease progression, I want to be honest that we're likely talking about weeks to a few months rather than longer.' KPS decline over time (especially ≥20 points/month) is a stronger predictor of imminent death than any single static score. Document KPS trends longitudinally.
All oncology providers
Use KPS as a trigger for early palliative care integration. ASCO guidelines recommend concurrent palliative care referral at the time of metastatic cancer diagnosis — KPS provides an objective measure to support this recommendation. Patients with KPS ≤70 at any point in their cancer trajectory should be offered palliative care consultation. For patients on active treatment, declining KPS (especially from ≥70 to ≤60) despite therapy signals treatment failure and should prompt discussion of treatment goals, advance care planning, and palliative care intensification. KPS ≤40 warrants urgent palliative care or hospice discussion.
Cancer registrars, outcomes researchers, and quality improvement teams
KPS is widely used in cancer outcomes research as a baseline functional status variable and prognostic covariate. Capture KPS systematically at baseline, each treatment cycle, and at disease progression for all cancer patients. This enables survival analyses stratified by performance status, quality metrics (e.g., proportion of patients receiving chemotherapy with KPS <50), and real-world effectiveness studies. Many national cancer registries and oncology quality programs (ASCO QOPI, NCQA oncology measures) require performance status documentation. Standardize KPS assessment within your institutional EHR using validated templates or smart phrases to improve data quality.
KPS and ECOG are the two most widely used performance status scales in oncology, and conversion between them helps when switching between systems or comparing across trials. Approximate conversion: KPS 100 = ECOG 0; KPS 80–90 = ECOG 1; KPS 60–70 = ECOG 2; KPS 40–50 = ECOG 3; KPS 10–30 = ECOG 4. The key clinical threshold is KPS ≥70 (ECOG ≤1) = standard treatment eligibility; KPS 50–60 (ECOG 2) = marginal, individual assessment needed; KPS ≤40 (ECOG 3–4) = generally not eligible for cytotoxic chemotherapy.
KPS 50 is defined as 'requires considerable assistance and frequent medical care' — a patient who needs help with most ADLs and has significant functional limitation. This threshold is used by Medicare and most insurance programs as one criterion supporting hospice eligibility for cancer patients with estimated life expectancy ≤6 months. When documenting KPS for hospice purposes, describe functional status clearly in free text: 'Patient requires assistance with bathing and dressing, unable to prepare meals independently, spends significant time in bed — KPS 50.' This supports the hospice certification and reflects the clinical picture accurately.
A patient's KPS at a single time point is less informative than the trajectory over time. Progressive KPS decline — particularly ≥20 points/month — is one of the strongest predictors of imminent death across cancer types. For example, a patient at KPS 70 who was KPS 90 three months ago and KPS 80 six weeks ago is showing accelerating functional decline that suggests a poor prognosis even if their current score seems 'adequate.' Track KPS systematically at each visit and document the trend explicitly: 'KPS 90 (month -3) → 80 (month -2) → 70 (month -1) → 60 today — declining trajectory.' This supports prognostic conversations and hospice timing.
A common error is to assign KPS based on tumor burden or disease stage rather than the patient's actual functional capacity. KPS should reflect what the patient CAN and CANNOT DO — not how sick they look on CT or how advanced their cancer is. A patient with widely metastatic melanoma who runs 5 miles/day is KPS 100. A patient with early-stage prostate cancer who requires a wheelchair for all mobility is KPS 30–40. Assess function through systematic history and observation, not through radiographic findings. This distinction matters because performance status determines treatment eligibility and prognosis, and it can be improved by addressing reversible causes (anemia, pain, infection, fluid overload).
When KPS is poor (≤50), systematically ask: is this due to reversible or irreversible causes? Reversible causes of poor KPS include: severe anemia (Hgb <8 g/dL — correct with transfusion or ESA), symptomatic pleural effusion (drain it), severe cancer pain (optimize opioids), delirium or encephalopathy (treat infection, metabolic cause), severe deconditioning from recent hospitalization (physical therapy), or untreated depression. A patient who is KPS 40 due to Hgb 6 may improve to KPS 70 after blood transfusion, restoring chemotherapy eligibility. Before declaring a patient 'too sick for treatment,' treat reversible contributors and reassess KPS after optimization.
Studies show that clinicians tend to round KPS upward (assign a more favorable score) when they have a therapeutic agenda (wanting to offer chemotherapy) or when they see a patient infrequently. Bedside nurses and family members who observe patients continuously often assign lower KPS scores than physicians who see patients briefly in clinic. To reduce this bias: (1) ask family and caregivers directly about functional capacity at home, (2) cross-check with occupational therapy or nursing assessments, (3) use ECOG and KPS as cross-references (they should be roughly concordant), (4) when in doubt, use the lower score. Under-assessing KPS severity can lead to chemotherapy administration that causes harm.
Performance status is the strongest predictor of chemotherapy toxicity risk, outperforming age in most studies. KPS 60–70 (ECOG 2) patients have a 2–3x higher risk of grade 3–4 toxicity from standard-dose chemotherapy compared to KPS 80–100 (ECOG 0–1) patients. When treating KPS 60–70 patients, consider: (1) Starting with dose-reduced regimens (80% of standard dose), (2) More frequent toxicity monitoring, (3) Prophylactic G-CSF from cycle 1, (4) Lower threshold for dose delay or reduction with toxicity. In elderly or frail patients, use geriatric assessment tools (Comprehensive Geriatric Assessment, CARG score) alongside KPS for more precise toxicity risk estimation.
KPS is a dynamic measure that should be reassessed and documented at every oncology visit, not just at initial evaluation. In patients on active therapy, KPS may improve (if the cancer responds and symptoms resolve) or decline (if treatment fails or toxicity accumulates). In palliative patients, KPS typically declines monotonically as disease progresses. A static KPS in the chart that was last updated 6 months ago is not reliable for current treatment decisions. Many EHR systems have KPS/ECOG fields in oncology flowsheets — populate these at every visit to enable longitudinal tracking and quality reporting.
KPS provides a global functional summary but has significant limitations as a standalone tool. It does not capture: disease-specific symptoms (pain, dyspnea, nausea), nutritional status (albumin, weight loss), cognitive function (important for treatment adherence), social support, patient values and preferences, or specific organ function (renal, hepatic, cardiac). In elderly cancer patients, supplement KPS with geriatric assessment (G8 screen, CARG score, polypharmacy review). In patients being considered for aggressive treatment, combine KPS with tumor biology, organ function labs, patient-reported outcomes, and goals-of-care discussions for holistic decision-making.
Karnofsky Performance Status was introduced by Karnofsky & Burchenal (Evaluation of Chemotherapeutic Agents, 1949). Inter-rater reliability is moderate (κ 0.5–0.7). KPS ≤50 is widely used for hospice eligibility criteria and palliative care thresholds. ECOG scale (Oken et al., Am J Clin Oncol 1982) is a 5-point simplified version validated with equivalent prognostic value. A systematic review by Péus et al. (Radiat Oncol 2013) confirmed KPS as a strong independent predictor of overall survival across tumor types.
Lower KPS values indicate higher functional impairment and generally worse prognosis across many oncology populations.
Use during baseline and follow-up oncology assessments, trial discussions, and palliative care planning.
KPS is subjective and can vary between observers. It also does not by itself identify the reversible causes of functional decline.
For related assessments, see ECOG Status, Clinical Frailty Scale and ASA Class.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Classify cancer patient performance status using the ECOG 0–5 scale. ECOG 0–1: eligible for standard chemotherapy. ECOG 2: limited self-care. ECOG 3+: significantly impaired, clinical trial caution.
OpenGeriatricsAssess frailty using the Rockwood Clinical Frailty Scale (CFS 1–9): Very Fit to Terminally Ill. Used for hospice eligibility, prognostication, ICU triage, surgical risk stratification, and goals-of-care discussions.
OpenSurgeryClassify preoperative physical status using the ASA I–VI system for anesthetic risk stratification. ASA III+ indicates significant systemic disease requiring special perioperative planning and precautions.
Open